Author Archive: Abigail Hirsch

Abigail Hirsch

Abigail is the Director of Events Communications at BIO. Although she has lived in the Washington, DC, area for nearly eight years, she still considers Virginia Beach home, especially with her parents and closest friends still in the area. According to Abigail, there is nothing better than sitting on the beach with a good book and cold drink. In her spare time, she enjoys visiting antique stores, finishing her twin sister Brooke’s sentences and spending time with her two boys, Frank her English bulldog, and JP her soon-to-be husband. Check back often for updates, Abigail’s take on BIO related events, and much more. And please, be kind, this is her first venture in to the blogging world!

Latest Posts

Industry Outlook in Anticipation of the 2012 BIO International Convention

HC5O7460

This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City at the Waldorf=Astoria. Hosted by BIO, the event drew more than 1,200 industry leaders, featured 140 company presentations and a record breaking 1,300+ one-on-one meetings between 225 companies. Taking the momentum from this meeting, we now look ahead to the 2012 BIO International Convention to be held June 18 – 21, 2012 at the Boston Convention & Exhibition Center in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

Stock Ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Approval for AIDS Vaccine at Canadian University

hiv-btn

The Food and Drug Administration has given Canadian researchers approval to test a vaccine for HIV/AIDS on humans. Researchers from the University of Western Ontario are hopeful that with further tests, a vaccine could be on the market in about five years. Similar to the approaches used to develop vaccines for polio, influenza, rabies and hepatitis A, the vaccine is the first based on a genetically modified, killed whole virus and is the only HIV Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Opportunity or Apocalypse? Prophecies for 2012

BIF Closing Plenary

On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,